Guangzhou Innogen Pharmaceutl Grp Co Ltd
HKSE: 2591.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Qinghua Wang
- Employees
- 105
- Headquarters
- Guangzhou, China
- IPO year
- 2025
- Market cap
- HK$5.8B
- Website
- http://www.innogenpharm.com
Loading 2591…
Loading profile data…Frequently asked questions about 2591
What does Guangzhou Innogen Pharmaceutl Grp Co Ltd (2591.HK) do?
Guangzhou Innogen Pharmaceutl Grp Co Ltd is a China-based investment holding company focused on the research, development, and commercialization of pharmaceutical products, particularly innovative, humanized, long-acting GLP-1 receptor agonists for diabetes and other metabolic diseases
Where does 2591.HK trade?
Guangzhou Innogen Pharmaceutl Grp Co Ltd (2591.HK) trades on the Hong Kong Stock Exchange.
What sector is 2591.HK in?
Guangzhou Innogen Pharmaceutl Grp Co Ltd (2591.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Guangzhou Innogen Pharmaceutl Grp Co Ltd?
Qinghua Wang is the chief executive officer of Guangzhou Innogen Pharmaceutl Grp Co Ltd (2591.HK).
Where is Guangzhou Innogen Pharmaceutl Grp Co Ltd headquartered?
Guangzhou Innogen Pharmaceutl Grp Co Ltd is headquartered in China.
Does 2591.HK pay a dividend?
Guangzhou Innogen Pharmaceutl Grp Co Ltd (2591.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2591.HK go public?
Guangzhou Innogen Pharmaceutl Grp Co Ltd (2591.HK) completed its initial public offering in 2025.